Millennium present data on kinase programs at EORTC-NCI-AACR meeting

Data presented at the EORTC NCI AACR meeting detail data and progress on Millennium kinase programs:
MLN8237 – Aurora A  – Phase II trials expected in late 2008/early 2009
TAK-285 – EGFR/HER dual kinase  -  Demonstrated good target specificity, pharmacokinetics and distribution and efficacy in EGFR- and HER2-expressing xenograft models
TAK-593 -VEGF/PDGF – Preclinical data show potent pseudo-irreversibility [...]

Boehringer Ingelheim provide update on kinase programs

Boehringer have provided a pipeline update including information on kinase inhibitors, and announces forthcoming presentations:
BIBW 2992 (Tovok) – EGFR/HER2 – Phase III study in NSCLC has commenced
BIBF 1120 – VEGFR, PDGFR, FGFR – Phase III in NSCLC is planned “in the near future”.
PLK-1 inhibitors – data to be presented at the upcoming 20th EORTC – [...]

GSK respond to negative NICE recommendation on Tykerb

GSK have responded to the NICE recommendationi that Tyverb (lapatinib) should not be used in the NHS, except in clinical trials. The company says “we strongly believe that the wrong decision has been made for patients, doctors and the NHS”

Abbott publish series of EGFR/ ErbB-2 inhibitor

Abbott have published a series of pyrrolidinyl-acetylenic thieno[3,2-d]pyrimidine EGFR/ ErbB-2 Inhibitors.

GSKs Tykerb (lapatinib) effective in advanced head and neck cancer

Phase II data presented at the European of Medical Oncology (ESMO) show that GSK’s Tykerb (lapatinib) is effective in advanced head and neck cancer

Vandetanib effective in xenograft models of sarcoma

AstraZeneca’s VEGFR2/EGFR inhibitor has shown activity against sarcoma cell lines in xenograft models

Wyeths EKB-569 safe in Phase I trials in Colorectal Cancer

Phase I data show Wyeths EGFR/HER2 inhibitor EKB-569 to be safe in colorectal cancer patients when administered in combination with capecitabine

Combination of a sheddase inhibitor INCB3619 with lapatinib improves anti-tumor effect

Researchers have shown that the addition of sheddase inhibitor INCB3619 to lapatinib treated cells increases antitumor activity

Phase II nimotuzumab data supports continued development

YM Biosciences have released Phase II data that show its EFGR antibody nimotuzumab to be effective in patients with irinotecan–refractory, metastatic colorectal cancer.

YM Biosciences EGFR MAb nimotuzumab safe in Phase I

Data to be presented at the AACR Centennial Conference on Translational Cancer Medicine today will detail YM Biosciences EGFR MAb nimotuzumab’s favorable side-effect profile. Data from an ongoing phase II study in colorectal cancer  has confirmed a low level of interaction between nimotuzumab and normal tissue with less than a quarter of the patients exhibiting [...]